Head to head
Dasatinib against Navitoclax
The two prescription senolytics with real human exposure, from opposite directions. Navitoclax is the most cited senolytic in mice and cannot be given to healthy people: in its first human trial 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia.
Column A
DasatinibDasatinib (senolytic; approved leukemia drug)
An FDA-approved leukemia drug repurposed as a senolytic with quercetin. The open-label pilots were promising; the randomised trials that followed were not.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Side by side, on the facts we can check
| Attribute | Dasatinib | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | FDA-approved for leukemia; senolytic use is off-label and investigational | Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov. |
| Half-life | ~3-5 hours | Not reported |
| Molecular weight | 488.0 Da | Not reported |
| Mechanism | Inhibits survival signaling in senescent cells, triggering their death, especially alongside quercetin. | Established in human cells and in mice: navitoclax is a BH3 mimetic that occupies the binding groove of BCL-2, BCL-xL and BCL-w, freeing pro-apoptotic BAX and BAK and triggering apoptosis in cells that depend on those proteins. In mice, that dependency is what makes senescent cells selectively vulnerable. In humans, the same dependency in platelets produces thrombocytopenia, verified in the oncology dose-escalation data. The senolytic selectivity demonstrated in mice has never been demonstrated in a person. |
| Human studies cited | 4 | 4 |
| Legal status, US | FDA-approved (for its labeled use), prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Dasatinib and Navitoclax?
Dasatinib: An FDA-approved leukemia drug repurposed as a senolytic with quercetin. The open-label pilots were promising; the randomised trials that followed were not. Navitoclax: The most-cited senolytic in mice, and the one that cannot be given to healthy people. In its first human trial, 29 of 55 patients with lymphoid cancers had grade 3 or 4 thrombocytopenia, because platelets survive on the same protein whose blockade kills senescent cells.
Which has stronger research evidence, Dasatinib or Navitoclax?
This database does not grade compounds. It counts what was run in people: 4 of the 6 studies cited on the Dasatinib profile were human work, against 4 of 7 for Navitoclax. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Dasatinib and Navitoclax FDA-approved?
Dasatinib: FDA-approved for leukemia; senolytic use is off-label and investigational. Navitoclax: Not approved for any indication, in any country. Investigational in oncology since 2006. No ageing or senescence indication is registered on ClinicalTrials.gov..
Related posts
Blog articles that cover Dasatinib or Navitoclax, newest first.
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 8, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 8, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Longevity / Sep 8, 2026 / 8 minKlotho Explained: Protein, Peptide, Gene Therapy or Supplement?
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.